Pazopanib/pazopanib usage and dosage

Pazopanib is indicated for the treatment of adults with advanced renal cell carcinoma (RCC) or advanced soft tissue sarcoma (STS) who have previously received chemotherapy. However, the efficacy of treating adipocyteSTS or gastrointestinal stromal tumors (GIST) in adult patients has not yet been proven. The usage and dosage of pazopanib include the following:

1. Recommended dose: The recommended dose of pazopanib is 800 mg (four 200 mg tablets), taken orally once a day without food (at least 1 hour before or 2 hours after a meal) until disease progression or unacceptable toxicity occurs. Pazopanib tablets should be swallowed whole. Do not crush tablets as absorption may be increased, which may affect systemic exposure. If a dose is missed, it should not be taken if it is less than 12 hours before the next dose.

2. Dose adjustment: For patients with liver damage and taking certain concomitant drugs, the dose should be modified. For patients with RCC, the first dose may be reduced to 400 mg orally once daily; the second dose may be reduced to 200 mg; for patients with STS, the first dose may be reduced to 600 mg orally once daily; the second dose may be reduced to 400 mg; patients who cannot tolerate the second dose reduction should permanently discontinue pazopanib.

(1) Hepatic Impairment:For patients with moderate hepatic impairment [total bilirubin >1.5 to 3 times the upper limit of normal (ULN) and any alanine aminotransferase (ALT) value], consider alternatives to pazopanib. If pazopanib is used in patients with moderate hepatic impairment, reduce the dose to 200 mg orally once daily. Pazopanib is not recommended for patients with severe hepatic impairment (total bilirubin > 3 × ULN and any ALT value).

3. Drug interactions:

(1)PotentCYP3A4 inhibitors: Avoid concurrent use of strongCYP3A4 inhibitors and use alternative concomitant medications that have little or no potential to inhibit CYP3A4. If coadministration of a strong CYP3A4 inhibitor is necessary, reduce the pazopanib dose to 400 mg.

(2)PotentCYP3A4 inducers: Avoid concurrent use of strongCYP3A4 inducers and use alternative concomitant medications that have no or minimal enzyme induction potential. Pazopanib is not recommended for patients taking long-term use of strong CYP3A4 inducers.

(3)Gastric acid reducers: Avoid concurrent use of gastric acid reducers. If this cannot be avoided, Consider using short-acting antacids instead of proton pump inhibitors (PPIs) and H2 receptor antagonists. Separate administration of short-acting antacids and pazopanib by several hours.

In short, pazopanib is an effective anti-tumor drug, but during use, you should strictly follow the doctor's recommendations and prescriptions, pay attention to safe medication, and promptly detect and deal with any adverse reactions to improve the treatment effect and protect the health of the patient.